<i>Plasmodium vivax</i> elimination from India may need therapeutic efficacy studies - Informed shift to artemisinin-based treatment.

ABSTRACT: India has significantly reduced its Plasmodium vivax (P. vivax, Pv) malaria burden. However, threat of chloroquine (CQ) resistance can undermine these gains. Artemisinin-based combination therapies (ACTs) have demonstrated superior efficacy compared to CQ, particularly in regions where resistance Pv has been confirmed. Their benefits include rapid parasite clearance, improved tolerability, effectiveness against mixed-species infections, and reduced relapse rates when combined with primaquine (PQ). While the World Health Organization recommends changing the first-line treatment if the total failure rate exceeds 10%, some countries have acted earlier based on surveillance of putative drug resistance molecular markers. In India, therapeutic efficacy studies (TES) coverage

SUBMITTER: Kathpalia M 

PROVIDER: S-EPMC12853776 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature